MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dementia"

  • 2025 International Congress

    Breaking Away From the Ivory Tower

    J. de (Kogarah, Australia)

    Objective: We describe the evolution of the Geriatric Flying Squad (GFS), a rapid response outreach team for residential aged care facilities (RACFs) in the local…
  • 2025 International Congress

    Prevalence, demographic characteristics of Parkinson disease and associated comorbidities: An analysis of the Colombian Ministry of Health official registry

    A. Rincon, C. Pantoja, J. Torres, C. Tamayo, D. Rosselli (Bogotá, Colombia)

    Objective: Conduct a descriptive analysis of the Colombian Parkinson’s disease population and its comorbidities using data from the Colombian Ministry of Health.Estimate the prevalence and…
  • 2025 International Congress

    Patient-derived α-synuclein seed amplification as a tool for evaluating small molecule aggregation inhibitors for Parkinson’s disease and Lewy Body Dementia therapeutics

    K. Luk, B. Li, S. Song, N. Newman (Cambridge, USA)

    Objective: To validate on-target engagement of disease-relevant ⍺-synuclein (a-syn) aggregates by WTX-607, WaveBreak’s small-molecule clinical candidate for Parkinson’s disease (PD) and Lewy body dementia (LBD),…
  • 2025 International Congress

    The Movement Disorders Society Unified Parkinson Disease Rating Scale Motor Subscore Is Not Associated With Future Parkinson Disease Milestones – an observational study using linked health administrative data

    P. Gros, S. Bronskill, S. Dorrance, X. Wang, M. Chiu, M. Farkouh, C. Marras (Toronto, Canada)

    Objective: To examine the association between time to Parkinson Disease (PD) health administrative data milestones and a one-year change in the Movement Disorders Society –…
  • 2025 International Congress

    Plasma P-tau217 detects Alzheimer’s co-pathology and predicts cognitive decline in Parkinson’s disease

    T. Tropea, P. Aldea Stevenson, M. Flitter, D. Meehan, A. Morris, M. Lu, L. Iaccarino, E. Collins, M. Hodsdon, L. Shaw, E. Lee, D. Weintraub, A. Chen-Plotkin, M. Mintun, A. Siderowf (Philadelphia, USA)

    Objective: The objectives of this study are to compare plasma phosphorylated tau-217 (P-tau217) levels in Parkinson’s disease (PD) with versus without Alzheimer’s disease (AD) copathology…
  • 2025 International Congress

    Multimodal Dissection of GALC Variants Linking Olfactory Deficits to Cognitive Decline in Parkinson’s Disease

    Y. Li, M. Zhong, J. Liu (shanghai, China)

    Objective: Olfactory dysfunction is highly prevalent and often precedes motor symptoms, making it a potential early biomarker for disease progression and cognitive decline in Parkinson's…
  • 2025 International Congress

    Metabolomics Profiling in Egyptian Patients with Alzheimer’s and Parkinson’s Diseases

    S. Abdelaziz, A. Helmy, E. Hamid, M. Salama, A. Shalash (Cairo, Egypt)

    Objective: To identify differential serum metabolites found in AD and PD patients and their correlations to clinical presentation in Egyptian patients. Background: There is a…
  • 2025 International Congress

    Neurodegeneration Biomarkers: Correlation between Hippocampal Volume and Cognitive Performance by MoCA Test in Parkinson’s Disease

    Y. Matuk Perez, E. Fernandez Calleja, D. Resendiz Gonzalez, JM. Esquivias Farías, S. Alcauter Solórzano, I. Zamorano-Rangel (Queretaro, Mexico)

    Objective: This study aims to examine the relationship between hippocampal volume, assessed through magnetic resonance imaging (MRI), and MoCA test scores in patients diagnosed with…
  • 2025 International Congress

    Sex Differences for Autopsy-Confirmed Prodromal Lewy Body Dementia

    F. Dino, L. Gunn-Sandell, A. Tsai, D. Carter, Y. Wang, E. Bayram (Aurora, USA)

    Objective: To assess sex differences in prodromal Lewy body dementia (LBD) compared to Alzheimer’s disease (AD) Background: Identifying LBD at the prodromal stage can provide…
  • 2025 International Congress

    Association between cognitive adverse effects of anticholinergic medication and development of long-term dementia in Parkinson’s disease

    SH. Ha, BR. Jin, SY. Kim, SM. Lee, JH. Shin, HJ. Kim (Seoul, Republic of Korea)

    Objective: To investigate whether cognitive adverse effects occurring immediately after taking anticholinergics are related to the development of long-term dementia and to interpret this from…
  • 1
  • 2
  • 3
  • …
  • 36
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley